BioCatalystWatch
VERUWorkspace / VERU / OverviewCompany library
Price
Market cap
Next catalystQ4 2026 — FDA pre-IND meetingSabizabulin — planned pancreatic-cancer Phase 2b study · Regulatory meetingCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Enobosarm

Androgen receptor (AR)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

PreINDP1P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

PreINDP1P3FilingApproved
Upcoming / outlook

Enobosarm

Androgen receptor (AR)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

Enobosarm

Androgen receptor (AR)

PreINDP1P2P3FilingApproved

Partner / License out

History / paused

Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

PreINDP1P2P3FilingApproved
Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

PreINDP1P2P3FilingApproved
Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

PreINDP1P2P3FilingApproved
Sabizabulin

β-tubulin (colchicine-binding site) × α-tubulin × β-tubulin

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status
1M1M

Market Reaction / Supply Context

Market Structure

VERU PR & News

PR & News

VERU SEC archive